MedTrace Logo

Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients

NCT00676988 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 327

Last updated 2012-06-14

No results posted yet for this study

Summary

To assess the relationship between the change in Crohn's Disease Activity Index (CDAI) scores and trough serum infliximab concentration in subjects who are scheduled to receive infliximab infusions at an interval of 8 weeks.

Conditions

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • University of Western Ontario, Canada

    lead OTHER

Principal Investigators

  • Brian G Feagan, MD · Director Clinical Trials

  • Gordon R Greenberg, MD · co-principal investigator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676988 on ClinicalTrials.gov